Ryan Specialty (NYSE:RYAN - Get Free Report) had its price target lowered by equities researchers at Keefe, Bruyette & Woods from $76.00 to $75.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Keefe, Bruyette & Woods' price objective suggests a potential upside of 1.60% from the stock's previous close.
Several other equities research analysts also recently weighed in on RYAN. UBS Group increased their target price on shares of Ryan Specialty from $82.00 to $84.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Royal Bank of Canada reduced their price objective on shares of Ryan Specialty from $73.00 to $72.00 and set a "sector perform" rating on the stock in a research report on Friday, February 21st. Finally, Wells Fargo & Company boosted their target price on Ryan Specialty from $64.00 to $69.00 and gave the company an "equal weight" rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, Ryan Specialty presently has a consensus rating of "Hold" and a consensus price target of $75.67.
View Our Latest Report on Ryan Specialty
Ryan Specialty Price Performance
Shares of NYSE:RYAN traded up $1.01 on Wednesday, reaching $73.82. The company's stock had a trading volume of 358,805 shares, compared to its average volume of 939,745. The company has a 50-day simple moving average of $70.05 and a 200 day simple moving average of $68.88. Ryan Specialty has a 52-week low of $48.48 and a 52-week high of $77.16. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.01 and a current ratio of 1.01. The company has a market cap of $19.33 billion, a P/E ratio of 106.99, a PEG ratio of 1.19 and a beta of 0.66.
Ryan Specialty (NYSE:RYAN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.02). Ryan Specialty had a return on equity of 48.01% and a net margin of 9.14%. The company had revenue of $663.53 million during the quarter, compared to analysts' expectations of $658.80 million. As a group, equities research analysts anticipate that Ryan Specialty will post 2.29 EPS for the current fiscal year.
Insider Activity at Ryan Specialty
In related news, EVP Brendan Martin Mulshine sold 30,000 shares of the company's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $69.30, for a total transaction of $2,079,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nicholas Dominic Cortezi sold 35,000 shares of the firm's stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $67.15, for a total value of $2,350,250.00. Following the sale, the director now directly owns 25,809 shares in the company, valued at approximately $1,733,074.35. The trade was a 57.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 211,894 shares of company stock worth $14,089,370 over the last three months. 11.10% of the stock is owned by corporate insiders.
Institutional Trading of Ryan Specialty
Hedge funds have recently modified their holdings of the company. UMB Bank n.a. raised its stake in shares of Ryan Specialty by 5.0% during the 1st quarter. UMB Bank n.a. now owns 5,797 shares of the company's stock worth $428,000 after acquiring an additional 275 shares in the last quarter. Procyon Advisors LLC acquired a new position in shares of Ryan Specialty during the first quarter worth $410,000. Baker Tilly Wealth Management LLC purchased a new stake in shares of Ryan Specialty during the 1st quarter valued at $247,000. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Ryan Specialty in the 1st quarter worth $215,000. Finally, GAMMA Investing LLC grew its stake in Ryan Specialty by 8,897.2% during the 1st quarter. GAMMA Investing LLC now owns 155,201 shares of the company's stock worth $11,465,000 after buying an additional 153,476 shares during the last quarter. 84.82% of the stock is owned by hedge funds and other institutional investors.
About Ryan Specialty
(
Get Free Report)
Ryan Specialty Holdings, Inc operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, Europe, and Singapore. It offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.
Further Reading
Before you consider Ryan Specialty, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ryan Specialty wasn't on the list.
While Ryan Specialty currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
